Newsdesk

Follow Medasense’s accomplishments and news

PMD-200 CE Approval

Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD-200.
This new technology is now available to help physicians objectively assess a patient’s pain in critical care situations, where patients are unable to communicate.  This allows physicians to ensure pain is properly managed.

To read the full PR click here.

Video Highlights

The essence of Medasense: Guiding critical care clinicians for optimal pain care

Meeting the challenge of intraoperative pain monitoring

Leading clinicians on the importance of monitoring the patient’s pain response level

Close Menu